

MEMO

TO: CCLS Clients

FROM: CCLS – Specimen Referral Center

DATE: 2/22/2021

SUBJECT: Antimicrobial Susceptibility, Aerobic Actinomycetes

Effective March 10, 2021, Mayo will be making changes to the following test:

ANTIMICROBIAL SUSCEPTIBILITY, AEROBIC ACTINOMYCETES (LAB00292664)

Explanation: The antimicrobial drug concentrations associated with this testing will be changing on the effective date with the implementation of an updated Sensititre panel to align with current Clinical and Laboratory Standards Institute recommendations.

CURRENT REFERENCE VALUES				
Antimicrobial agent	Concentration range mcg/mL	Interpretations		
		S	I	R
Amikacin	1-64	< or =8	-	> or =16
Amoxicillin/clavulanate	2/1-64/32	< or =8/4	16/8	> or =32/16
Ceftriaxone	4-64	< or =8	16-32	> or =64
Ciprofloxacin	0.12-4	< or =1	2	> or =4
Clarithromycin	0.06-16	< or =2	4	> or =8
Doxycycline	0.12-16	< or =1	2-4	> or =8
Imipenem	2-64	< or =4	8	> or =16
Linezolid	1-32	< or =8	-	-
Minocycline	1-8	< or =1	2-4	> or =8
Moxifloxacin	0.25-8	< or =1	2	> or =4
Tobramycin	1-16	< or =4	8	> or =16
Trimethoprim/ Sulfamethoxazole	0.25/4.75-8/152	< or =2/38	-	> or =4/76

NEW REFERENCE VALUES				
Antimicrobial agent	Concentration range mcg/mL	Interpretations		
		S	I	R
Amikacin	0.5-32	< or =8	-	> or =16
Amoxicillin/clavulanate	2/1-128/64	< or =8/4	16/8	> or =32/16
Ceftriaxone	1-64	< or =8	16-32	> or =64
Ciprofloxacin	0.12-16	< or =1	2	> or =4
Clarithromycin	0.03-16	< or =2	4	> or =8
Doxycycline	0.12-16	< or =1	2-4	> or =8
Imipenem	0.12-32	< or =4	8	> or =16
Linezolid	0.5-16	< or =8	-	-
Minocycline	0.06-16	< or =1	2-4	> or =8
Moxifloxacin	0.015-8	< or =1	2	> or =4
Tobramycin	2-64	< or =4	8	> or =16
Trimethoprim/ Sulfamethoxazole	0.06/1.19-8/152	< or =2/38	-	> or =4/76
For <i>Rhodococcus equi</i> only				
Rifampin	0.5-2	< or =1	2	> or =4
Vancomycin	0.5-16	< or =2	4-8	> or =16

Please feel free to contact the Specimen Referrals Center with any questions at 320-251-2700 Ext. 57320